La Jolla Pharmaceutical Company
LJPC
LJPC was delisted on the 19th of August, 2022.
73 hedge funds and large institutions have $79.4M invested in La Jolla Pharmaceutical Company in 2020 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 21 increasing their positions, 24 reducing their positions, and 14 closing their positions.
3% more capital invested
Capital invested by funds: $76.8M → $79.4M (+$2.55M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 14
5% less funds holding
Funds holding: 77 → 73 (-4)
13% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 24
18% less call options, than puts
Call options by funds: $464K | Put options by funds: $563K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$19.8M |
| 2 |
Morgan Stanley
New York
|
+$1.62M |
| 3 |
FMBTD
First Midwest Bank Trust Division
Joliet,
Illinois
|
+$822K |
| 4 |
BC
Boxer Capital
San Diego,
California
|
+$731K |
| 5 |
Two Sigma Investments
New York
|
+$460K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.53M |
| 2 |
Goldman Sachs
New York
|
-$1.15M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$1.12M |
| 4 |
SG Americas Securities
New York
|
-$770K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
-$512K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
D.E. Shaw & Co
New York
| – | -$288K | -73,167 | Closed |
|
|
GCP
77
GSA Capital Partners
London,
United Kingdom
| – | -$222K | -56,542 | Closed |
|
|
OAM
78
Oxford Asset Management
Oxford,
United Kingdom
| – | -$212K | -53,943 | Closed |
|
79
Squarepoint
New York
| – | -$123K | -31,390 | Closed |
|
80
State of Wisconsin Investment Board
Madison,
Wisconsin
| – | -$114K | -29,100 | Closed |
|
|
CSS
81
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$98K | -24,971 | Closed |
|
|
TRCT
82
Tower Research Capital (TRC)
New York
| – | -$33K | -8,399 | Closed |
|
|
RCC
83
Red Cedar Capital
Omaha,
Nebraska
| – | -$10K | -2,500 | Closed |
|
|
VFA
84
Valeo Financial Advisors
Carmel,
Indiana
| – | -$2K | -500 | Closed |
|
85
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$1K | -1 | Closed |
|
|
CG
86
Cutler Group
San Francisco,
California
| – | +$632 | +100 | New |
|
LJPC Hedge Fund Activity: Q1 2020 in Review
73 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in La Jolla Pharmaceutical Company (LJPC) for Q1 2020, worth a combined $79.4M — up 3.3% from $76.8M a quarter earlier.
Fund positioning in LJPC was balanced in Q1 2020: 14 funds opened new positions, 14 closed out, 21 added to existing stakes and 24 trimmed.
The largest buyer was Tang Capital Management, adding an estimated $19.8M. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $2.53M sold.
- 73 institutional investors held La Jolla Pharmaceutical Company (LJPC) as of Q1 2020, down from 77 in Q4 2019.
- Funds reported $79.4M of La Jolla Pharmaceutical Company stock for Q1 2020, up 3.3% quarter-over-quarter.
- 14 funds opened new La Jolla Pharmaceutical Company positions in Q1 2020 and 14 closed out, a net change of 0 holders.
- The largest La Jolla Pharmaceutical Company buyer in Q1 2020 was Tang Capital Management, an estimated $19.8M added.
- The largest La Jolla Pharmaceutical Company seller in Q1 2020 was Alyeska Investment Group, an estimated $2.53M sold.
Based on aggregated 13F filings for Q1 2020.